Comparative efficacy study of experimental chronic heart failure

Introduction. Combination therapy of chronic heart failure (CHF) is an urgent and important treatment strategy, as it allows to achieve an improvement in the prognosis, optimal control of the symptoms of the disease and an increase in the quality of life of patients. Aim. Comparison of the effectiveness of the malonic acid derivative ethmaben, the sodium-glucose cotransporter inhibitor empagliflozin and their combinations with the variability of the starting drug in experimental post-infarction chronic heart failure in rats. Materials and methods. In a model of post-infarction chronic heart failure, reproduced by permanent ligation of the left coronary artery in rats, an echocardiographic study was used to compare etmaben and empagliflozin monotherapy with a combined regimen of these drugs. The concentration of etmaben in the myocardium was assessed by HPLC. Results and discussion. Antagonism between etmaben and empagliflozin was revealed, manifested by a decrease in the effect of combination therapy in relation to any of the components, a decrease in the concentration of malonic acid derivative in the myocardium under the action of a type 2 sodium-glucose cotransporter inhibitor was shown. Conclusion. Based on the data obtained, additional studies of pharmacokinetics and pharmacodynamics of etmaben were planned.